Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: Society of Gynecologic Oncology and ASCO Clinical Practice Guideline Summary

2016 ◽  
Vol 12 (12) ◽  
pp. 1254-1257 ◽  
Author(s):  
Alexi A. Wright ◽  
Kari Bohlke ◽  
Mitchell I. Edelson
Keyword(s):  
Ovarian Cancer ◽  
Clinical Practice ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Gynecologic Oncology ◽  
Advanced Ovarian Cancer ◽  
Newly Diagnosed ◽  
Cancer Society

scholarly journals Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline

2013 ◽  
Vol 4 (4) ◽  
pp. 263
Author(s):  
Brendan J.W. Miles ◽  
Adrian S. Fairey ◽  
Michael Eliasziw ◽  
Eric P. Estey ◽  
Peter Venner ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Oncology Group ◽  
Chimiothérapie Néoadjuvante ◽  
Cancer De La Vessie ◽  
Before And After ◽  
Muscle Invasive

Introduction: The objective of this study was to compare referraland treatment rates of neoadjuvant chemotherapy for patients withmuscle-invasive bladder cancer before and after publication of aclinical practice guideline.Methods: This was a retrospective comparative cohort study of236 patients diagnosed with clinical stage ≥ T2 bladder cancerin Alberta, Canada. Patients were divided into 2 groups basedon the time of diagnosis relative to the publication of the AlbertaGenitourinary Oncology Group Clinical Practice Guideline onBladder Cancer (CPG), which recommends cisplatin-based neoadjuvantchemotherapy for muscle-invasive disease. The pre-CPGgroup included patients (n = 129) diagnosed prior to publicationof the CPG (November 1, 2002 to October 31, 2004, inclusively).The post-CPG group included patients (n = 107) diagnosed afterpublication of the CPG (November 1, 2005 to October 31, 2007).There was an accrual blackout period of 6 months before and afterthe CPG release date. The primary analysis compared the twogroups with respect to neoadjuvant chemotherapy referral rates,treatment-offered rates and treatment-administered rates.Results: Referral to medical oncology regarding neoadjuvantchemotherapy occurred in 2.3% and 23.4% of patients in thepre- and post-CPG groups, respectively (p < 0.01). Neoadjuvantchemotherapy was offered to 0.8% and 18.7% of patients in thepre- and post-CPG groups, respectively (p < 0.01). Neoadjuvantchemotherapy was administered to 0.8% and 14.0% of patients inthe pre- and post-CPG groups, respectively (p < 0.01).Interpretation: Neoadjuvant referral and treatment rates increasedafter publication of the CPG. However, overall referral and treatmentrates remained low, which warrants additional exploration.Introduction : L’objectif de l’étude était de comparer les taux derecommandation et de traitement par chimiothérapie néoadjuvantechez les patients atteints de cancer de la vessie avec envahissementmusculaire avant et après la publication d’un guide de pratiqueclinique.Méthodologie : Il s’agit ici d’une étude comparative rétrospectivede cohorte comptant 236 patients de l’Alberta, au Canada, chezqui on avait diagnostiqué un cancer de la vessie de stade cliniqueT2 ou pire. Les patients ont été répartis en 2 groupes selon que leurdiagnostic avait été posé avant ou après la publication du guidede pratique clinique sur le cancer de la vessie (GPC) de l’AlbertaGenitourinary Oncology Group, qui recommande une chimiothérapienéoadjuvante à base de cisplatine pour le traitement descas de cancer avec envahissement musculaire. Le groupe pré-GPCcomprenait des patients (n = 129) chez qui le diagnostic avaitété posé avant la publication du GPC (du 1er novembre 2002 au31 octobre 2004, inclusivement). Le groupe post-GPC incluait despatients (n = 107) chez qui le diagnostic avait été posé après lapublication du GPC (du 1er novembre 2005 au 31 octobre 2007).Une période cumulative de censure a été calculée 6 mois avant etaprès la date de publication du GPC. L’analyse préliminaire a comparéles deux groupes quant aux taux de recommandation de lachimiothérapie néoadjuvante, aux taux d’offre et d’administrationdu traitement.Résultats : La chimiothérapie néoadjuvante a été recommandée chez2,3 et 23,4 % des patients dans les groupes pré-GPC et post-GPC,respectivement (p < 0,01). Elle a été offerte à 0,8 % et 18,7 % despatients de ces mêmes groupes (p < 0,01), et administrée à 0,8 et14,0 % des patients des groupes pré-GPC et post-GPC, respectivement(p < 0,01).Interprétation : Les taux de recommandation et de traitement concernantla chimiothérapie néoadjuvante ont augmenté après lapublication du GPC, mais sont tout de même demeurés faibles,ce qui nécessite une analyse plus poussée.

The Japanese Breast Cancer Society clinical practice guideline for radiotherapy of breast cancer

Breast Cancer ◽  
2014 ◽  
Vol 22 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Kenji Sekiguchi ◽  
Yasuhiro Ogawa ◽  
Naoko Sanuki ◽  
Satoko Arahira ◽  
Etsuyo Ogo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Cancer Society ◽  
Japanese Breast Cancer Society

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition

Breast Cancer ◽  
2016 ◽  
Vol 23 (3) ◽  
pp. 329-342 ◽  
Author(s):  
Tomohiko Aihara ◽  
Tatsuya Toyama ◽  
Masato Takahashi ◽  
Yutaka Yamamoto ◽  
Fumikata Hara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Systemic Treatment ◽  
Cancer Society ◽  
Japanese Breast Cancer Society

scholarly journals The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline

2009 ◽  
Vol 96 (1) ◽  
pp. 71-83 ◽  
Author(s):  
Minesh P. Mehta ◽  
Nina A. Paleologos ◽  
Tom Mikkelsen ◽  
Paula D. Robinson ◽  
Mario Ammirati ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Brain Metastases ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Evidence Based ◽  
Newly Diagnosed

scholarly journals Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective

2017 ◽  
Vol 35 (6) ◽  
pp. 587-590 ◽  
Author(s):  
Christina Fotopoulou ◽  
Jalid Sehouli ◽  
Giovanni Aletti ◽  
Philipp Harter ◽  
Sven Mahner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
European Perspective ◽  
Newly Diagnosed

The Japanese Breast Cancer Society Clinical Practice Guideline for screening and imaging diagnosis of breast cancer

Breast Cancer ◽  
2014 ◽  
Vol 22 (1) ◽  
pp. 28-36 ◽  
Author(s):  
Mitsuhiro Tozaki ◽  
Ichiro Isomoto ◽  
Yasuyuki Kojima ◽  
Kazunori Kubota ◽  
Yoshifumi Kuroki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Imaging Diagnosis ◽  
Cancer Society ◽  
Japanese Breast Cancer Society
Sign in / Sign up

Export Citation Format

Share Document